Literature DB >> 15517160

Severe vagal response after endotoxin administration in humans.

Lucas T G J van Eijk1, Peter Pickkers, Paul Smits, Martijn P W J M Bouw, Johannes G van der Hoeven.   

Abstract

OBJECTIVE: Endotoxin administration to humans is a common means to study systemic inflammation. Worldwide, thousands of volunteers have received endotoxin, and adverse events are rarely reported. The aim of this report was to increase awareness of specific risks of the intravenous administration of endotoxin to human volunteers.
DESIGN: Report of four cases who developed severe bradycardia or protracted asystole after administration of endotoxin. Interviews with investigators at three large centers that conduct normal volunteer endotoxin studies.
SETTING: Clinical research unit. CASES: Four subjects developed severe bradycardia or protracted asystole, approximately 1 h after administration of endotoxin. Further analyses revealed that the subjects had a history of vasovagal syncope or a positive head-tilt test, indicating increased vagal sensitivity. Relative volume depletion associated with fasting overnight may have predisposed these subjects to this condition.
CONCLUSIONS: These responses are very rare and are likely due to the cardioinhibitory Bezold-Jarisch reflex. A thorough screening regarding a history of vagal sensitivity and liberal oral or intravenous fluid administration prior to and during the endotoxin challenge may decrease the risk of these events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517160     DOI: 10.1007/s00134-004-2477-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  9 in total

1.  Asystole following endotoxin administration.

Authors:  W V Williams; T Fullerton; J C Fox; M B Enslin; L Murray; D Jorkasky
Journal:  J Endotoxin Res       Date:  2000

2.  Guidelines on management (diagnosis and treatment) of syncope.

Authors:  M Brignole; P Alboni; D Benditt; L Bergfeldt; J J Blanc; P E Bloch Thomsen; J G van Dijk; A Fitzpatrick; S Hohnloser; J Janousek; W Kapoor; R A Kenny; P Kulakowski; A Moya; A Raviele; R Sutton; G Theodorakis; W Wieling
Journal:  Eur Heart J       Date:  2001-08       Impact factor: 29.983

3.  Increased activity in left ventricular receptors during hemorrhage or occlusion of caval veins in the cat. A possible cause of the vaso-vagal reaction.

Authors:  B Oberg; P Thorén
Journal:  Acta Physiol Scand       Date:  1972-06

4.  Ventricular syncope: is the heart a sensory organ?

Authors:  F M Abboud
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

5.  The cardiovascular response of normal humans to the administration of endotoxin.

Authors:  A F Suffredini; R E Fromm; M M Parker; M Brenner; J A Kovacs; R A Wesley; J E Parrillo
Journal:  N Engl J Med       Date:  1989-08-03       Impact factor: 91.245

6.  Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects. Influence of elicited hormones and cytokines.

Authors:  R P Richardson; C D Rhyne; Y Fong; D G Hesse; K J Tracey; M A Marano; S F Lowry; A C Antonacci; S E Calvano
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

Review 7.  Response of man to endotoxin.

Authors:  G D Martich; A J Boujoukos; A F Suffredini
Journal:  Immunobiology       Date:  1993-04       Impact factor: 3.144

8.  Integrative aspects of a human model of endotoxemia.

Authors:  C A Ottaway; I W Fong; B da Silva; W Singer; L Karrass
Journal:  Can J Physiol Pharmacol       Date:  1998-05       Impact factor: 2.273

9.  Hemorrhagic shock with paradoxical bradycardia.

Authors:  P Barriot; B Riou
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

  9 in total
  8 in total

1.  Safety of endotoxin challenge in healthy volunteers: bradycardia.

Authors:  Bernd Jilma
Journal:  Intensive Care Med       Date:  2005-02-12       Impact factor: 17.440

2.  Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.

Authors:  Christopher Geven; Dirk van Lier; Alice Blet; Roel Peelen; Bas Ten Elzen; Alexandre Mebazaa; Matthijs Kox; Peter Pickkers
Journal:  Br J Clin Pharmacol       Date:  2018-07-03       Impact factor: 4.335

3.  Hypoxia attenuates inflammation-induced hepcidin synthesis during experimental human endotoxemia.

Authors:  Dorien Kiers; Lucas T van Eijk; Johannes G van der Hoeven; Dorine W Swinkels; Peter Pickkers; Matthijs Kox
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

4.  Characterization of a model of systemic inflammation in humans in vivo elicited by continuous infusion of endotoxin.

Authors:  D Kiers; R M Koch; L Hamers; J Gerretsen; E J M Thijs; L van Ede; N P Riksen; M Kox; P Pickkers
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

5.  A randomized double-blind, placebo-controlled clinical phase IIa trial on safety, immunomodulatory effects and pharmacokinetics of EA-230 during experimental human endotoxaemia.

Authors:  Roger van Groenendael; Matthijs Kox; Guus Leijte; Bouke Koeneman; Jelle Gerretsen; Lucas van Eijk; Peter Pickkers
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

6.  Comparison of different lots of endotoxin and evaluation of in vivo potency over time in the experimental human endotoxemia model.

Authors:  Dorien Kiers; Guus P Leijte; Jelle Gerretsen; Jelle Zwaag; Matthijs Kox; Peter Pickkers
Journal:  Innate Immun       Date:  2019-01       Impact factor: 2.680

7.  Transcutaneous vagal nerve simulation to reduce a systemic inflammatory response syndrome and the associated intestinal failure: study protocol of a prospective, two-armed, sham-controlled, double-blinded trial in healthy subjects (the NeuroSIRS-Study).

Authors:  Cornelius J van Beekum; Martin W von Websky; Maria A Willis; Christina Panknin; Martin Coenen; Rolf Fimmers; Jörg C Kalff; Sven Wehner; Tim O Vilz
Journal:  Int J Colorectal Dis       Date:  2021-10-02       Impact factor: 2.571

8.  Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation.

Authors:  James N Fullerton; Elisabetta Segre; Roel P H De Maeyer; Alexander A N Maini; Derek W Gilroy
Journal:  J Vis Exp       Date:  2016-05-16       Impact factor: 1.355

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.